Jade Biosciences, Inc. (JBIO)
JBIO Stock Price Chart
Explore Jade Biosciences, Inc. interactive price chart. Choose custom timeframes to analyze JBIO price movements and trends.
JBIO Company Profile
Discover essential business fundamentals and corporate details for Jade Biosciences, Inc. (JBIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Apr 2025
Employees
50.00
Website
https://jadebiosciences.comCEO
Tom Frohlich
Description
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
JBIO Financial Timeline
Browse a chronological timeline of Jade Biosciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.46.
Earnings released on 13 Aug 2025
EPS came in at -$0.86 falling short of the estimated -$0.43 by -100.00%.
Dividend declared on 29 Apr 2025
A dividend of $84.00 per share was announced, adjusted to $2.40.
Stock split effective on 29 Apr 2025
Shares were split 1 : 35 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 25 Apr 2025
EPS came in at -$0.09 surpassing the estimated -$8.40 by +98.93%.
Earnings released on 27 Mar 2025
EPS came in at -$0.19 matching the estimated -$0.19.
JBIO Stock Performance
Access detailed JBIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.